In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies, and there is insufficient evidence regarding potential harm to humans
While BPC/TB-15 contains three times the standard concentration, side effects remain generally minimal and similar to lower doses when used under medical supervision
It's the best I have felt in months
Disguised Alpha reviews analytical documentation, identity support, purity documentation, product presentation, labeling accuracy, storage expectations, and release suitability before products are made available
c) How You Can Protect Your Information: If You would like to disable Our access to any passive information We receive from the use of various technologies, You may choose to disable cookies in Your web browser